Oral antifungal therapies for toenail onychomycosis: a systematic review with network meta-analysis toenail mycosis: network meta-analysis

References

• Gupta AK, Versteeg SG, Shear NH. Onychomycosis in the 21st century: an update on diagnosis, epidemiology, and treatment. J Cutan Med Surg. 2017;21(6):525–539.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Mays RR. The impact of onychomycosis on quality of life: a systematic review of the available literature. Skin Appendage Disord. 2018;4(4):208–216.
   PubMed Web of Science ®Google Scholar
• Milobratovic D, Jankovic S, Vukicevic J, et al. Quality of life in patients with toenail onychomycosis. Mycoses. 2013;56(5):543–551.
   PubMed Web of Science ®Google Scholar
• Szepietowski JC, Reich A, National Quality of Life in Dermatology Group, Stigmatisation in onychomycosis patients: a population-based study. Mycoses. 2009;52(4):343–349.
   PubMed Web of Science ®Google Scholar
• Vlahovic TC, Joseph WS, Scher RK, et al. Diagnosis and management of onychomycosis perspectives from a joint podiatric medicine-dermatology roundtable. J Am Podiatr Med Assoc. 2016;106(2):155–162.
   PubMed Web of Science ®Google Scholar
• Rajpar SF, Abdullah A. Management of onychomycosis and awareness of guidelines among dermatologists. Br J Dermatol. 2006;155(5):1080–1082.
   PubMed Web of Science ®Google Scholar
• Eertmans F, Doss N, Rossel B, et al. Daily application of an aqueous, acidifying, peelable nail polish versus weekly amorolfine for topical onychomycosis treatment: a prospective, randomized, blinded trial. Dermatol Ther. 2018;8(3):463–473.
   Web of Science ®Google Scholar
• Eisman S, Sinclair R. Fungal nail infection: diagnosis and management. BMJ. 2014;348(3):g1800–g1800.
   PubMedGoogle Scholar
• Gupta G, Mallefet P, Kress DW, et al. Adherence to topical dermatological therapy: lessons from oral drug treatment. Br J Dermatol. 2009;161(2):221–227.
   PubMed Web of Science ®Google Scholar
• Brautigam M. Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. J Am Acad Dermatol. 1998;38(5):S53–S56.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Gregurek-Novak T. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatol. 2001;202(3):235–238.
   PubMed Web of Science ®Google Scholar
• Jones HE, Zaias N. Double-blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. Int J Dermatol. 1996;35(8):589–590.
   PubMed Web of Science ®Google Scholar
• Odom R, Daniel CR, Aly R. A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. J Am Acad Dermatol. 1996;35(1):110–111.
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Elewski BE, Rich PA, et al. Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison. J Dermatolog Treat. 2006;17(1):38–44.
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, van Rossem K, Malahias S, et al. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. J Am Acad Dermatol. 2013;69(3):416–425.
   PubMed Web of Science ®Google Scholar
• Succi IB, Bernardes-Engemann AR, Orofino-Costa R. Intermittent therapy with terbinafine and nail abrasion for dermatophyte toe onychomycosis: a pilot study. Mycoses. 2013;56(3):327–332.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of Interventions Version 5.1. 0: Cochrane. London: The Cochrane Collaboration; 2011.
   Google Scholar
• Tonin FS, Rotta I, Mendes AM, et al. Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract. 2017;15(1):943–943.
   PubMed Web of Science ®Google Scholar
• Mills EJ, Bansback N, Ghement I, et al. Multiple treatment comparison meta-analyses: a step forward into complexity. Clin Epidemiol. 2011;3:193–202.
   PubMedGoogle Scholar
• Gupta AK, Daigle D, Foley KA. Network meta-analysis of onychomycosis treatments. Skin Appendage Disord. 2015;1(2):74–81.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Foley KA, Mays RR, et al. Monotherapy for toenail onychomycosis: a systematic review and network meta-analysis. Br J Dermatol. 2019;182(2):287–299.
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–784.
   PubMed Web of Science ®Google Scholar
• Moher D, Tetzlaff J, Tricco AC, et al. Epidemiology and reporting characteristics of systematic reviews. PLoS Med. 2007;4(3):e78.
   PubMed Web of Science ®Google Scholar
• Turner RM, Davey J, Clarke MJ, et al. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. 2012;41(3):818–827.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. Evidence synthesis for decision making: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33(5):641–656.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013;11(1):159.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. Statist Med. 2010;29(7–8):932–944.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol. 1996;23(4):259–262.
   PubMedGoogle Scholar
• Baran R, Belaich S, Beylot C, et al. Comparative multicentre double-blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. J Dermatolog Treat. 1997;8(2):93–97.
   Web of Science ®Google Scholar
• Billstein S, Mph Kianifard F, et al. Terbinafine vs. placebo for onychomycosis in black patients. Int J Dermatol. 1999;38(5):377–379.
   PubMed Web of Science ®Google Scholar
• Brautigam M, Nolting S, Schopf RE, et al. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ. 1995;311(7010):919–922.
   PubMedGoogle Scholar
• Brautigam M, Nolting S, Schopf RE, et al. German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. Br J Dermatol. 1996;134:18–21.
   PubMed Web of Science ®Google Scholar
• De Backer M, De Vroey C, Lesaffre E, et al. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double- blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol. 1998;38(5):S57–S63.
   PubMed Web of Science ®Google Scholar
• Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol. 1997;37(5):740–745.
   PubMed Web of Science ®Google Scholar
• Elewski B, Pollak R, Ashton S, et al. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol. 2012;166(2):389–398.
   PubMed Web of Science ®Google Scholar
• Ellis DH, Marley JE, Watson AB, et al. Significance of non-dermatophyte moulds and yeasts in onychomycosis. Dermatology. 1997;194(1):40–42.
   PubMedGoogle Scholar
• Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ. 1999;318(7190):1031–1035.
   PubMed Web of Science ®Google Scholar
• Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol. 1995;32(5):750–753.
   PubMed Web of Science ®Google Scholar
• Finlay A, Thomas R, Dykes P, et al. Descriptive correlations between various doses of oral terbinafine and concentrations in nail. J Dermatol Treatment. 1994;5(4):193–197.
   Google Scholar
• Goodfield MJ. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol. 1992;126(s39):33–35.
   PubMedGoogle Scholar
• Goodfield MJ, Andrew L, Evans EG. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ. 1992;304(6835):1151–1154.
   PubMedGoogle Scholar
• Gupta AK, Konnikov N, Lynde CW. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J Am Acad Dermatol. 2001;44(3):479–484.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Leonardi C, Stoltz RR, et al. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venerol. 2005;19(4):437–443.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Lynch LE, Kogan N, et al. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol. 2009;23(3):256–262.
   PubMed Web of Science ®Google Scholar
• Haneke E, Tajerbashi M, De Doncker P, et al. Itraconazole in the treatment of onychomycosis: a double-blind comparison with miconazole. Dermatology. 1998;196(3):323–329.
   PubMed Web of Science ®Google Scholar
• Havu V, Heikkila H, Kuokkanen K, et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol. 2000;142(1):97–102.
   PubMed Web of Science ®Google Scholar
• Hofmann H, Brautigam M, Weidinger G, et al. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. Arch Dermatol. 1995;131(8):919–922.
   PubMedGoogle Scholar
• Honeyman JF, Talarico FS, Arruda LHF, et al. Itraconazole versus terbinafine (LAMISIL®): Which is better for the treatment of onychomycosis? J Eur Acad Dermatol Venereol. 1997;9(3):215–221.
   Web of Science ®Google Scholar
• Ling MR, Swinyer LJ, Jarratt MT, et al. Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38(6):S95–S102.
   PubMed Web of Science ®Google Scholar
• Pajaziti L, Vasili E. Treatment of onychomycosis – a clinical study. Med Arh. 2015;69(3):173–176.
   Google Scholar
• Ranawaka RR, Nagahawatte A, Gunasekara TA, et al. Randomized, double-blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: a study with 90 patients. J Dermatolog Treat. 2016;27(4):364–372.
   PubMed Web of Science ®Google Scholar
• Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38(6):S77–S86.
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Olafsson JH, Steinsson JB, et al. Long-term effectiveness of treatment with terbinafine vs. itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol. 2002;138(3):353–357.
   PubMedGoogle Scholar
• Svejgaard EL, Brandrup F, Kragballe K, et al. Oral terbinafine in toenail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months' follow-up. Acta Derm Venereol. 1997;77(1):66–69.
   PubMed Web of Science ®Google Scholar
• Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol. 1996;34(4):595–600.
   PubMed Web of Science ®Google Scholar
• Warshaw EM, Fett DD, Bloomfield HE, et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2005;53(4):578–584.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Tsubouchi I, Okubo A. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. J Dermatol. 2018;45(10):1151–1159.
   PubMed Web of Science ®Google Scholar
• Watson A, Marley J, Ellis D, et al. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol. 1995;33(5):775–779.
   PubMed Web of Science ®Google Scholar
• Yadav P, Singal A, Pandhi D, et al. Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: A randomized double-blind trial. Indian J Dermatol Venereol Leprol. 2015;81(4):363–369.
   PubMed Web of Science ®Google Scholar
• Zhang L, Xu H, Shi Y, et al. An exploration of the optimum dosage and number of cycles of itraconazole pulse therapy for severe onychomycosis. Mycoses. 2018;61(10):736–742.
   PubMed Web of Science ®Google Scholar
• Crawford F, Young P, Godfrey C, et al. Oral treatments for toenail onychomycosis: a systematic review. Arch Dermatol. 2002;138(6):811–816.
   PubMedGoogle Scholar
• Kreijkamp-Kaspers S, Hawke K, Guo L, et al. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017;7:CD010031.
   PubMedGoogle Scholar
• Gupta AK, Daigle D, Paquet M. Therapies for onychomycosis a systematic review and network meta-analysis of mycological cure. J Am Podiatr Med Assoc. 2015;105(4):357–366.
   PubMed Web of Science ®Google Scholar
• Ameen M, Lear JT, Madan V, et al. British association of dermatologists’ guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014;171(5):937–958.
   PubMed Web of Science ®Google Scholar
• Westerberg DP, Voyack MJ. Onychomycosis: current trends in diagnosis and treatment. Am Fam Physician. 2013;88(11):762–770.
   PubMed Web of Science ®Google Scholar
• Lipner SR, Scher RK. Onychomycosis: treatment and prevention of recurrence. J Am Acad Dermatol. 2019;80(4):853–867.
   PubMed Web of Science ®Google Scholar
• Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet. 2001;40(6):441–472.
   PubMed Web of Science ®Google Scholar
• Dietz AJ, Barnard JC, van Rossem K. A randomized, double-blind, multiple-dose, placebo-controlled, dose escalation study with a 3-cohort parallel group design to investigate the tolerability and pharmacokinetics of albaconazole in healthy subjects. Clin Pharmacol Drug Dev. 2014;3(1):25–33.
   PubMed Web of Science ®Google Scholar
• Hay RJ. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol. 2001;145(S60):3–8.
   PubMedGoogle Scholar